Skip to main content
    A

    Axsome Therapeutics Inc (AXSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $141.69
    -2.68 (-1.86%)

    Market Cap: $7.45B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Axsome Therapeutics Inc (AXSM) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Axsome Therapeutics (AXSM) trades at 8.6x sales and 70.5x book value. Its P/S of 8.6x is below its 5-year median of 13.9x. Its forward P/E is 29.5x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E29.5x
    Price to sales8.6x
    Price to book70.5x
    PEGN/A
    FCF yield-1.1%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 145.6% above 28.7x.

    MultipleCurrent5-year median10-year median
    P/S8.6x13.9xN/A
    P/B70.5x67.1x28.7x
    Medians of month-end values through Oct 2026: 53 to 60 months (5-year) and 117 months (10-year).

    Valuation History

    Over the 4 of the 10 year ends shown that have a P/S, its P/S ranged from 10.5x in 2024 to 64.8x in 2022.

    Year endPriceP/SP/B
    2025$182.6414.3x104.7x
    2024$84.6110.5x72.0x
    2023$79.5913.3x19.7x
    2022$77.1364.8x30.6x
    2021$37.78N/A91.3x
    2020$81.47N/A26.7x
    2019$103.36N/AN/A
    2018$2.82N/A89.8x
    2017$5.60N/A8.1x
    2016$6.75N/A6.0x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About AXSM

    What is AXSM's forward P/E ratio?

    Axsome Therapeutics has a forward P/E ratio of 29.5x.

    Is AXSM stock overvalued?

    GNG's valuation label for AXSM is Fairly valued.

    What is AXSM's price to sales ratio?

    Axsome Therapeutics has a price to sales ratio of 8.6x.